Resverlogix Presents at Biotech Showcase During JP Morgan Week
News Jan 15, 2015
Resverlogix Corp. has announced that Donald McCaffrey, president and chief executive officer presented at the 7th Annual Biotech Showcase Conference 2015 during JP Morgan week. The presentation can be accessed via the following link: http://edge.media-server.com/m/p/5wz2z9gn.
Mr. McCaffrey was excited to share developments of the Company's proposed new phase 3 clinical trial BETONMACE. "This trial represents an unprecedented opportunity to reduce major adverse coronary events "MACE" in patients with diabetes. RVX-208 is the only selective BET-Bromodomain inhibitor in clinical trials to reduce the risk of death by cardiac events in patients with CVD and diabetes."
Drug Discovery Alliance Formed to Help Increase Drug Development Success RateNews
Two prominent preclinical safety companies have launched a unique European alliance to address the high safety-related failure rate in drug development.READ MORE
First Ever Online Event Focused on Cannabis ScienceNews
Analytical Cannabis is pleased to announce that the final line-up of speakers for the first ever cannabis science online event, The Science of Cannabis 2017 has been confirmed.READ MORE
Autism Risk Higher if Pregnant Mothers Have Infection Requiring HospitalizationNews
Studies have shown that mothers who experience an infection severe enough to require hospitalization during pregnancy are at higher risk of having a child with autism.READ MORE